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As recent studies highlight the importance of alternative mechanisms in the control of bone turnover, new
therapeutic approaches can be envisaged for bone diseases and periodontitis-induced bone loss. Recently, it has
been shown that Fluoxetine and Venlafaxine, serotonin re-uptake inhibitors commonly used as antidepressants, can
positively or negatively affect bone loss in rat models of induced periodontitis. Serotonin is a neurotransmitter that
can be found within specific nuclei of the central nervous system, but can also be produced in the gut and be
sequestered inside platelet granules. Although it is known to be mainly involved in the control of mood, sleep, and
intestinal physiology, recent evidence has pointed at far reaching effects on bone metabolism, as a mediator of the
effects of Lrp5, a membrane receptor commonly associated with Wnt canonical signaling and osteoblast
differentiation. Deletion of Lrp5 in mice lead to increased expression of Tryptophan Hydroxylase 1, the gut isoform
of the enzyme required for serotonin synthesis, thus increasing serum levels of serotonin. Serotonin, in turn, could
bind to HTR1B receptors on osteoblasts and stop their proliferation by activating PKA and CREB.
Although different groups have reported controversial results on the existence of an Lrp5-serotonin axis and the
action of serotonin in bone remodeling, there is convincing evidence that serotonin modulators such as SSRIs can
affect bone turnover. Consequently, the effects of this drug family on periodontal physiology should be thoroughly
explored.
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A recent study by Branco-de-Almeida [1] showed that
ligature-induced periodontitis in rats could be ame-
liorated by Fluoxetine, a selective serotonin re-uptake
inhibitor (SSRI), a class of molecules that can increase
serotonin levels by inhibiting its clearance inside synap-
ses and are commonly used as antidepressant and as an
effective treatment for mood disorders [2]. Carvalho
et al., however, showed in this Journal that Venlafaxine,
a member of the same drug class, increased bone loss in
a rat model of induced periodontitis [3]. These studies
raise the question whether and how SSRIs, and therefore
serotonin, may affect alveolar bone and the outcome of
periodontitis. The issue is of the utmost importance
because it could help elucidate poorly known aspects of
periodontal pathophysiology in the context of the ongoing* Correspondence: guidomaria.macaluso@unipr.it
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reproduction in any medium, provided the ordebate in bone metabolism, paving the way, if possible, to
new therapeutic approaches. As the relation of serotonin
and bone is still fiercely debated, the same controversy
that has been troubling the bone field seems to be heading
for periodontics.Serotonin
Serotonin, or 5-hydroxytryptamine (5-HT), is a monoamine
produced within the central nervous system, mostly in
neurons located in the raphe nuclei [4], which send nume-
rous projections to different brain regions, such as the
striatum, hippocampus and frontal cortex [5]. Serotonin
acts as a neurotransmitter by being released into the synap-
tic cleft, where it binds to post synaptic receptors. DA
transporters (DAT) and 5-HT transporters (5-HTT) collect
serotonin from the synaptic cleft and store it in cytoplasmic
vescicles in presynaptic neurons, a process commonly refer-
red to as re-uptake, thus regulating the duration of the
stimulus. The serotoninergic transmission has a broad
spectrum of effects and has been associated to neural. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[7-11] and to central modulation of pain [12]. Serotonin,
however, can also be synthesized by heterochromaffin cells
in the gut, where it regulates gastrointestinal function [13],
by endothelial cells in the lung [14] and can be found
sequestered inside platelet granules [15,16]. As sero-
tonin cannot cross the hematoencephalic barrier, it
forms two physically and functionally separated pools,
the former inside the central nervous system and the
latter in the peripheral body. Although its best known
roles are the control of mood, sleep/wake rhythm, peri-
stalsis and mucus secretion, a big but not uncontrover-
sial amount of evidence has been recently reported
showing that serotonin may actually exert far reaching
effects on bone.
A growing amount of evidence in the literature has also
shown that the use of SSRIs is significantly associated to
increased risk of fracture [17-23], to increased levels of
bone resorption markers [24] and administrating SSRIs
during pregnancy is associated to shorter length and
smaller head circumference in newborns, albeit with un-
affected bone quality [25]. Moreover, the frequency of
serotonin transporter gene 5-HTTVNTR polymorphism
was observed to be higher in osteoporotic patients [26]
and 5-HTT polymorphism has been associated to BMD
changes after SSRI treatment [21]. Noteworthy, a cross-
sectional study by Costa et al. reported an association
between aggressive periodontitis and serotonin trans-
porter 5-HTTLPR polymorphism, which has reduced
transcriptional efficiency and is associated with lower
serotonin re-uptake, in the Brazilian population [27].
The Wnt connection
Our understanding of the role of serotonin has however
been considerably increased by studying genetic diseases
in human and the effect of alterations in the LRP5 protein.
LRP5 is a membrane protein that is commonly believed to
function by dimerizing with transmembrane receptors of
the Frizzled family and activating the canonical WNT sig-
naling pathway upon binding to WNT Growth Factors
[28-30]. The activation of the canonical pathway requires
the recruitment of Disheveled (Dvl) [31,32], which rescues
beta catenin from degradation. Beta catenin can be nor-
mally found in two pools within the cell, either bound to
cadherins in cell-to-cell junctions or in the cytoplasm,
where it is sequestered by a destruction complex that
targets it for proteosomal degradation [33-36]. Once beta
catenin is released, following activation of the receptor
complex, it can translocate to the nucleus and bind to a
member of the T cell factor/lymphoid enhancer factor
(TCF/Lef1) transcription factor family [37,38]. The cano-
nical WNT signaling is required for osteoblast differen-
tiation, bone formation and even bone maintenance
through osteoclast inhibition [39-41].It is well known that loss of function or gain of func-
tion mutations in the Lrp5 gene lead respectively to a
low or high bone mass phenotype, as clinically observed
in Osteoporosis Pseudoglioma Syndrome (OPPG) and
the High-bone-mass Syndrome (HBM) [42,43] and the
majority of researchers interpret this as the result of
Wnt signaling inhibition in osteoblasts. Yadav et al.
however showed that deletion of Lrp5 gene in mice lead
to increased expression of Tryptophan Hydroxylase 1
(Tph1), the gut isoform that is required for 5-HT syn-
thesis [44]. As a consequence, serum levels of serotonin
were increased in Lrp5 knock-out homozygous and hete-
rozygous mice. Their findings are in agreement with
numerous clinical observations in OPPG and HBM
patients [45-47] and suggest that altered LRP5 functio-
nality may be acting on bone at a distance by regulating
circulating levels of serotonin, which would then bind to
specific receptors on bone cells, and not directly by
controlling Wnt signaling in bone cells, as commonly
maintained (Figure 1). Strikingly, ex vivo experiments
revealed that 50 mM 5-HT could indeed stop osteoblast
proliferation by binding to the HTR1B receptor and acti-
vating PKA and CREB transcription factor [44], although
previous independent results showed that lower (0.1 mM)
doses of serotonin could enhance the proliferation of
human primary osteoblasts in vitro [48], suggesting a
possible dose-dependent effect. According to Yadav et al.
tryptophan-free diet could rescue the bone phenotype in
Lrp5−/− mice and, importantly, conditional Lrp5 deletion
in the gut increased bone mass [44]. In agreement with
these observations, Laporta et al. reported that feeding
5-hydroxy-l-tryptophan to rats from day 13 of preg-
nancy through day 9 of lactation increased total serum
and milk calcium concentrations, osteoclast numbers in
bone and bone mRNA levels for resorption markers
[49]. Other researchers however have gathered solid
evidence supporting the idea that Lrp5 does act locally
in bone and does not require serotonin. Niziolek et al.
reported an Lrp5 gain-of -function mutation associated
with high bone mass in mice without concomitant
alterations in circulating serotonin levels [50]. Most
strikingly, the same group also showed that global Tph1
deletion did not affect bone mass in their mouse model, in
strong contrast to Yadav’s data [51], and Gustafsson et al.
reported that administration of 5 mg/kg/day serotonin
subcutaneously for 3 months increased Bone Mineral
Density and cortical thickness, although reduced trabecu-
lar thickness [52].
The pre-clinical observations in rats by Carvalho et al.
and Branco-de-Almeida et al. reflect this controversy
and do not manage to resolve the conundrum on
whether and how 5-HT acts on bone and periodontium.
Unfortunately, neither Carvalho nor Branco-de-Almeida
considered the role of serotonin in planning their studies
Figure 1 Diagram depicting the two alternative models for Lrp5 action. According to the former, “central”, serotonin-mediated model
(left-hand side), activation of Lrp5 inhibits Tryptophan Hydroxylase 1 (Tph1) and reduces circulating levels of Serotonin, thus decreasing its
inhibitory effect on osteoblasts via its HTR1B receptor. According to the “peripheral” serotonin-independent model (right-hand side), Lrp5 acts
directly on osteoblasts initiating the canonical Wnt signal cascade and inducing beta catenin translocation to the nucleus and activation of its
transcriptional program.
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did not measure serotonin levels in untreated and
treated rats. However, measuring serum serotonin is
arguably not an easy task and this could also help explain
the discordant results in the literature [53]. Carvalho tes-
ted both a low (10 mg/kg/day) and a high (50 mg/kg/day)
dose of Venlafaxine per os, whereas only a single but high
dose of Fluoxetine (20 mg/kg/day) was used by Branco-
de-Almeida, similarly orally administered, so, although it
is reasonable to assume that serotonin levels were affected
in both studies, it is hard to guess the real extent of it.
Moreover, Fluoxetine has been shown to directly reduce
osteoblast proliferation and decrease the Osteoprotegerin/
Receptor Activator of Nuclear kB Factor Ligand (RANKL)
ratio in vitro, thus possibly promoting osteoclastogenesis
[48]. Consistently with these results, a 6 month low dose
(5 mg/kg/day) treatment with Fluoxetine in rats has been
shown to reduce trabecular thickness and increase
endocortical bone volume [54]. The dose of Fluoxetine
tested by Branco-de-Almeida et al. was on the high end
of the doses commonly used to suppress serotonin
production in rats [55,56], about twice as high as the
maximum recommended human dose (MRHD) [54],
and was based on a previous work highlighting its anti-
inflammatory properties [57]. It is actually possible
that this high dose of Fluoxetine may be activatingalternative immunomodulatory or antiinflammatory
pathways that are responsible for the authors’ observa-
tions and that are overcoming the effects on serotonin
metabolism. Indeed Branco-de-Almeida et al. showed
that Fluoxetine inhibited IL-1β and COX-2 mRNA and
metalloprotease (MMP) 9 activity in their model, and,
consistently with these findings, it has been reported
that 5 mg/kg i.p Fluoxetine can reduce the expression of
MMP 2 and 9 in rat hippocampus [58] and 10 mg/kg i.p.
Fluoxetine inhibits the expression of MMP 2, 9 and 12
after spinal cord injury in mouse [59]. A recent study
found that SSRIs can differentially control osteoclast and
osteoblast viability, apoptosis and activity [60]. Fluoxetine
in particular proved to affect preosteoclast viability to a
greater extent than other drugs of this class, and this
could help explain its effect on periodontitis. Furthermore,
it cannot be ruled out that at least part of the positive
effects of Fluoxetine on periodontitis could be explained
through its action on the central nervous system, where it
has been shown that Fluoxetine can increase Tph expres-
sion [56,61]. Strikingly, Yadav et al. showed that deletion
of the brain stem specific Tryptophan Hydroxylase 2
(Tph2) isoform, lead to a reduction in bone mass in mice,
apparently activating an alternative and opposite me-
chanism to the one mediating the effects of the gut Tph
isoform [62]. Both the amount of serotonin and its
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on bone. Different drugs at different doses might even
prevalently act on or have higher affinity for one isoform
of the enzyme and the net effect observed on bone could
be the result of the systemic suppression of both enzymes.
The controversy is therefore still open and further
studies that address this issue in detail are sorely needed.
Perspectives
One of the most exciting aspects of bone mass control
by serotonin is the possibility to positively affect bone
formation at a distance without acting directly on bone
cells, and thus the possibility of a novel therapeutic
target to improve the outcome of periodontal disease
and alveolar bone regenerative techniques. As of today, a
novel compound, LP533401, has been generated and
tested in rodents [63,64]. LP533401 can selectively inhi-
bit Tph1 when administered per os, and significantly
reduce serotonin levels in blood without passing the
hematoencephalic barrier and affect brain’s serotonin
concentration. It has been shown that LP533401 can
increase bone mass and reduce ovariectomy-induced
bone loss in rodents [63,64], even if its active enantio-
mer, LP923941, was independently proven to be unable
to do so [50]. It has not been investigated yet whether
LP533401 can affect alveolar bone.
Another equally fascinating aspect of the relation bet-
ween serotonin and Lrp5 is the possibility, if confirmed,
to elucidate some hitherto poorly known regulatory
mechanisms in bone physiology. A central dogma of
bone biology is that bone tissue is constantly remodeled
by teams of dedicated cells that resorb bone, the osteo-
clasts, and cells that form new tissue, the osteoblasts.
These cells act in a tightly coordinated fashion so that
bone formation and bone resorption are coupled, be-
cause these two processes occur simultaneously and
affect each other. It has been shown that osteoclasts can
mobilize sequestered osteogenic factors such as TGFb1
from the mineralized matrix during resorption, stimula-
ting osteoblasts and presumably contributing to sustain
bone formation in the osteoclastic lacuna [65]. It is also
known that cells of the osteoblastic lineage can produce
RANKL at different stages of differentiation [66,67], thus
controlling osteoclast formation and survival. This poses
significant limits to anabolic therapies, which could sig-
nificantly benefit from the possibility to differentially
control these processes, according to a patient’s clinical
needs. Noteworthy, Lrp5 deletion in mice, a genotype
recapitulating the human OPPG syndrome [68], is
mainly a bone formation phenotype, whereas hypomor-
phism of LRP6, a closely related molecule, has been
shown to lead to low bone mass due to increased bone
resorption [69]. A better understanding of this difference
and the different signaling cascades that are locateddownstream, such as possibly serotonin, could indeed
unravel the secret to uncoupling bone formation and
resorption, with huge therapeutical benefits.
Although the available results in rodents are just preli-
minary, they are undoubtedly captivating and are an open
invitation to further investigate the role of serotonin not
only in bone physiology but also on periodontal phy-
siology and pathology.
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